Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Animal Type (Canine, Feline, Equine), By Vaccination (Canine Family, Feline Family, Others), By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines), By Region, By Competition

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4500

Multi-User Licence

$5500

Custom Research Licence

$8000

Summary

Request Sample

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 9.04 billion
CAGR (2023-2028)	5.93%
Fastest Growing Segment	Injectable Vaccines
Largest Market	North America

Market Overview

Global Pet Vaccine Market has valued at USD 9.04 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6% through 2028. COVID-19 has impacted the growth of the Pet Vaccine market. The Pet Vaccine Market is a rapidly evolving segment within the global veterinary healthcare industry. It encompasses a wide range of vaccines specifically designed to safeguard the health and well-being of companion animals, such as dogs, cats, and other household pets. This market has been witnessing significant growth due to several key drivers. Firstly, rising pet ownership and increasing awareness about the importance of preventative healthcare measures for pets have fueled the demand for vaccines. Pet owners are increasingly inclined to protect their furry companions from various diseases, resulting in a steady market expansion. Secondly, advancements in vaccine technology and research are driving the development of newer and more effective vaccines. These innovations are enabling the prevention of a broader spectrum of diseases and improving the overall efficacy and safety of pet vaccines.

Additionally, stringent regulations and guidelines related to pet healthcare and vaccination are fostering the growth of this market by ensuring the quality and safety of pet vaccines. Furthermore, the growing prevalence of zoonotic diseases, which can be transmitted between animals and humans, has emphasized the importance of vaccinating pets as a public health measure, further boosting market growth. Overall, the Pet Vaccine Market is characterized by ongoing research and development, increasing pet adoption rates, and a growing emphasis on animal welfare, making it a promising and vital segment of the veterinary healthcare industry.

Key Market Drivers

Increasing prevalence of diseases in companion animals

The Pet Vaccine Market is experiencing robust growth due to the escalating prevalence of diseases in companion animals. This trend is driven by various factors, which collectively emphasize the critical role of vaccines in safeguarding the health of pets. Firstly, the increase in pet ownership worldwide has led to a higher concentration of animals in urban areas and shared environments. This proximity can facilitate the rapid spread of diseases among companion animals, making vaccination an essential preventive measure. Secondly, emerging and re-emerging infectious diseases pose a significant threat to pets. These diseases not only impact animal health but can also potentially transmit to humans, highlighting the public health importance of vaccination in pets. Thirdly, lifestyle changes in pet owners have led to greater exposure of animals to disease vectors like ticks, fleas, and mosquitoes, which can transmit various pathogens. This heightened risk underscores the necessity of vaccines tailored to protect against vector-borne diseases.

Moreover, the globalization of pet travel has increased the risk of disease transmission across borders, emphasizing the need for comprehensive vaccination protocols. Furthermore, advancements in veterinary medicine and an increased understanding of immunology have led to the development of more efficacious and safer vaccines, driving higher acceptance among pet owners. In conclusion, the escalating prevalence of diseases in companion animals is a compelling driver for the Pet Vaccine Market, underscoring the importance of preventive healthcare measures to ensure the well-being of pets and reduce the risk of zoonotic disease transmission. This trend is likely to sustain the market's growth in the foreseeable future.

Growing awareness of disease prevention

The growing awareness of disease prevention is a potent driver propelling the expansion of the Pet Vaccine Market. This heightened awareness is multifaceted, encompassing several critical aspects. Firstly, pet owners are becoming increasingly conscious of the importance of preventative healthcare measures for their beloved animal companions. They recognize that vaccinations are a proactive way to shield pets from a range of potentially life-threatening diseases. This awareness has led to a more responsible approach to pet care and a willingness to invest in vaccines to ensure their pets' well-being.

Secondly, access to information has played a pivotal role in raising awareness. Pet owners now have easy access to a wealth of information through the internet, social media, and veterinary professionals, allowing them to stay informed about the latest developments in pet healthcare, including the importance of vaccinations. Thirdly, the devastating impact of certain diseases on pets has garnered significant media attention. Outbreaks of diseases like canine distemper and parvovirus serve as stark reminders of the risks companion animals face. These incidents have driven home the importance of vaccinations as a crucial defense against such threats. Additionally, veterinarians and pet healthcare providers play a pivotal role in educating pet owners about vaccination schedules and the significance of timely immunization. Their guidance reinforces the awareness and underscores the need for regular vaccination. In summary, the growing awareness of disease prevention in the context of pet healthcare is a major catalyst behind the Pet Vaccine Market's growth. It reflects a broader societal shift toward responsible pet ownership and a commitment to ensuring the long-term health and happiness of our animal companions. This trend is expected to continue driving market expansion in the coming years.

Download Free Sample Report

Key Market Challenges

Vaccine hesitancy among some pet owners

Vaccine hesitancy among some pet owners poses a significant challenge to the Pet Vaccine Market. This reluctance or refusal to vaccinate pets stems from various factors and can have far-reaching consequences.

Firstly, misinformation and misconceptions about vaccines can lead pet owners to doubt their safety and efficacy. Unverified claims about vaccine-related risks, often circulated on social media and other platforms, can fuel anxiety and hesitancy. Such misinformation can discourage pet owners from following recommended vaccination schedules, leaving their animals vulnerable to preventable disease. Secondly, the perception of over-vaccination can contribute to hesitancy. Concerns about potential side effects or perceived unnecessary booster shots may lead some pet owners to delay or skip vaccinations, putting their pets at risk. While guidelines for vaccination have evolved to reduce the frequency of boosters, this perception still lingers. Moreover, economic factors can play a role. Some pet owners may delay or forgo vaccinations due to financial constraints, particularly in underserved communities.

This vaccine hesitancy not only endangers individual pets but also compromises herd immunity. When a significant portion of the pet population remains unvaccinated, it creates pockets of susceptibility, increasing the risk of disease outbreaks. To address this challenge, education campaigns, transparent communication by veterinarians, and debunking vaccine-related myths are essential. Promoting the benefits of vaccines and their role in preventing suffering and saving lives is crucial in ensuring the overall health and well-being of companion animals and the continued growth of the Pet Vaccine Market.

Developing vaccines for emerging and evolving diseases in companion animals.

Developing vaccines for emerging and evolving diseases in companion animals presents a significant challenge for the Pet Vaccine Market. Several factors contribute to the complexity of this challenge. Emerging diseases often have unique characteristics, such as novel pathogens or rapidly mutating strains. Developing effective vaccines requires in-depth research and understanding of these complex disease agents, which can be time-consuming and resource-intensive.

Diseases in companion animals, like canines and felines, can evolve quickly. Adapting vaccines to keep pace with these evolving pathogens is a constant struggle. Frequent updates to vaccines may be necessary, posing logistical and regulatory challenges. Conducting clinical trials for new vaccines demands time and resources. Ensuring safety and efficacy in companion animals, who may have diverse genetic backgrounds, ages, and health statuses, can be particularly challenging. Pet vaccines must meet stringent regulatory requirements, adding complexity to the development process. Regulatory agencies often demand comprehensive safety and efficacy data before approving new vaccines. The market for companion animal vaccines is smaller compared to human vaccines, making it less attractive to vaccine developers. The potential return on investment may not always justify the research and development costs, particularly for diseases with limited geographic distribution.

High development costs can result in expensive vaccines, which may limit access for some pet owners, particularly in lower-income regions. Despite these challenges, the importance of developing vaccines for emerging and evolving diseases in companion animals cannot be overstated. It is crucial for protecting animal health, preventing zoonotic disease transmission, and ensuring the well-being of pets. Overcoming these obstacles requires collaboration between researchers, veterinarians, pharmaceutical companies, and regulatory bodies to drive innovation and expand the Pet Vaccine Market.

Key Market Trends

Increasing demand for personalized pet vaccines

The increasing demand for personalized pet vaccines represents a notable trend in the Pet Vaccine Market. This trend reflects a growing recognition that not all pets are alike, and tailoring vaccines to an individual animal's specific needs can yield significant benefits. Personalized pet vaccines involve customizing vaccination schedules and formulations based on factors such as a pet's age, breed, lifestyle, and geographic location. This approach ensures that each pet receives the most appropriate and effective protection against diseases, optimizing their overall health and minimizing unnecessary vaccinations. Advances in veterinary diagnostics, including genetic testing and serological assays, allow for a more precise understanding of a pet's immune status and susceptibility to specific diseases. This information can inform personalized vaccine recommendations. Pet owners increasingly view their pets as members of the family and are willing to invest in their well-being. They seek out veterinary practices that offer tailored healthcare plans, including personalized vaccines, to ensure the best outcomes for their pets.

Concerns about over-vaccination have led to a more selective approach to vaccinations. Personalization allows veterinarians to minimize unnecessary vaccinations, reducing the potential for adverse reactions and vaccine-related health issues. Regional disease prevalence varies, and some areas may have specific disease risks. Personalized vaccines can address these geographical variations, providing pets with targeted protection. In summary, the demand for personalized pet vaccines is driven by a shift toward individualized pet care and a desire to optimize vaccine effectiveness while minimizing risks. This trend aligns with the broader movement toward personalized medicine and is likely to continue shaping the Pet Vaccine Market in the coming years.

Growth in the use of mRNA technology in pet vaccine development

The growth in the use of mRNA (messenger RNA) technology in pet vaccine development is an emerging and transformative trend within the Pet Vaccine Market. This trend mirrors the groundbreaking advances in human vaccine development, such as the COVID-19 mRNA vaccines, and is poised to revolutionize how vaccines are created and administered for companion animals. mRNA technology allows for the rapid development and modification of vaccines, making it particularly suitable for addressing emerging diseases or evolving pathogens in pets. This agility in vaccine design can be crucial in outbreak situations. Traditional vaccine production methods often require time-consuming processes with live or inactivated pathogens. mRNA vaccines can be produced more quickly and with fewer manufacturing challenges, potentially accelerating vaccine availability.

mRNA vaccines are highly specific and do not use live pathogens, reducing the risk of adverse reactions. They can also be finely tuned to induce strong and targeted immune responses, potentially leading to enhanced vaccine efficacy. mRNA technology allows for the customization of vaccines to suit individual pet characteristics, optimizing protection while minimizing unnecessary components. As pets can transmit diseases to humans (zoonoses), mRNA vaccines for pets can contribute to public health by reducing the risk of disease transmission between animals and humans. While mRNA technology holds tremendous promise, its adoption in the Pet Vaccine Market is still in its early stages. Regulatory approval, manufacturing scalability, and cost-effectiveness are areas that require further development. Nevertheless, this trend represents a significant leap forward in pet vaccine development, promising safer, more effective, and adaptable vaccines to safeguard the health of companion animals.

Segmental Insights

Animal Type Insights

Based on the Animal Type, Canines play a dominant role in the Pet Vaccine Market due to their sheer numbers and close companionship with humans. Dogs are among the most popular pets globally, with extensive vaccination requirements for diseases like rabies, distemper, parvovirus, and canine influenza. Their susceptibility to various zoonotic diseases emphasizes the public health aspect of canine vaccination. Moreover, ongoing advancements in canine vaccine research, including personalized and mRNA-based vaccines, continue to drive innovation and market growth. As a result, the Pet Vaccine Market's focus on canines remains central, addressing both the well-being of dogs and the broader concerns of disease transmission between pets and humans.

Mode Of Administration Insights

Injectable vaccines dominate the Pet Vaccine Market due to their effectiveness, established track record, and ease of administration. These vaccines are preferred for several key reasons. Firstly, injectable vaccines are highly effective in stimulating a strong and long-lasting immune response in pets. They provide reliable protection against a wide range of diseases, including rabies, distemper, and parvovirus, among others. Secondly, injectable vaccines have a well-established safety profile. Veterinarians are familiar with their use, and adverse reactions are relatively rare, ensuring pet owners' confidence in their pets' health. Thirdly, the precise dosing and administration of injectable vaccines ensure consistent protection. This is particularly important for core vaccines, which are critical for preventing severe and potentially deadly diseases. Fourthly, regulatory approvals and guidelines often prioritize injectable vaccines, reinforcing their dominance in the market. Many countries mandate injectable rabies vaccines for pets, further boosting their prevalence.

Additionally, the ease of storage and transportation of injectable vaccines makes them practical for both veterinary clinics and pet owners. They do not require the complex storage conditions that some other vaccine types may necessitate. While emerging technologies like oral and nasal vaccines offer potential advantages, injectable vaccines remain the gold standard for pet immunization. They offer a proven and trusted method for safeguarding the health of companion animals, contributing to their continued dominance in the Pet Vaccine Market.

Download Free Sample Report

Regional Insights

North America stands as the dominant region in the Pet Vaccine Market for several compelling reasons. Firstly, North America has a substantial and growing pet population, with dogs and cats being among the most popular companion animals. The region's high pet ownership rates, combined with strong healthcare awareness, contribute significantly to the demand for pet vaccines. Secondly, North America boasts a well-developed veterinary infrastructure, including a large number of veterinary clinics and hospitals, research institutions, and pharmaceutical companies specializing in pet healthcare. This infrastructure supports the distribution, administration, and development of pet vaccines. Thirdly, stringent regulations and vaccination requirements are common in North American countries. For instance, rabies vaccination is often mandated by law to protect both pets and public health. These regulatory frameworks create a stable and robust market for pet vaccines. Fourthly, a culture of responsible pet ownership prevails in North America, with many pet owners prioritizing their pets' health and well-being. This mindset drives the demand for preventative healthcare measures, including vaccinations.

Moreover, the region is at the forefront of veterinary research and innovation, continually advancing the development of new and improved vaccines. It leads in the adoption of emerging technologies, such as mRNA-based vaccines, which enhance the efficacy and safety of pet vaccines. In conclusion, North America's combination of a large and health-conscious pet population, a well-established veterinary infrastructure, stringent regulations, and ongoing innovation makes it the dominant force in the Pet Vaccine Market. This leadership is likely to persist as the region continues to prioritize pet healthcare and well-being.

Recent Developments

In July 2022, the University of Wisconsin School of Veterinary Medicine and two other institutions started a clinical trial for vaccination against canine cancer study to develop a vaccine that would prevent dogs from developing cancer in the first place.
In September 2022, Kerala Government initiated a month-long vaccination drive for all stray dogs to deal with the stray dog menace in the state. This initiative and key developments create a demand for canine vaccines, thereby boosting the canine pet vaccine market size.
In 2020. Elanco, a global animal health company, completed the acquisition of Bayer Animal Health. This merger expanded Elanco's portfolio of injectable vaccines for pets, including for companion animals such as dogs and cats.

Key Market Players

Bayer AG
Elanco US Inc.
Merck KGaA
Merial Inc.
Virbac SA
Zoetis Inc
Phibro Animal Health Corporation
Boehringer Ingelheim GmbH
Tianjin Ringpu Bio-Technology Co., Ltd
Vetoquinol SA

By Animal Type	By Vaccination	By Mode of Administration	By Region
Canine Feline Equine	Canine Family Feline Family Others	Injectable Vaccines Intranasal Vaccines	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type:

o Canine

o Feline

o Equine

Pet Vaccine Market, By Vaccination:

o Canine Family

o Feline Family

o Others

Pet Vaccine Market, By Mode Of Administration:

o Injectable Vaccines

o Intranasal Vaccines

Pet Vaccine Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Pet Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pet Vaccine Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Animal Type (Canine, Feline, Equine)

5.2.2. By Vaccination (Canine Family, Feline Family, Others)

5.2.2.1. By Canine Family (Core Vaccines, Non-Core Vaccines)

5.2.2.2. By Feline Family (Core Vaccines, Non-Core Vaccines)

5.2.3. By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines)

5.2.4. By Region

5.2.5. By Company (2022)

5.3. Market Map

6. North America Pet Vaccine Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Animal Type

6.2.2. By Vaccination

6.2.3. By Mode of Administration

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Pet Vaccine Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Animal Type

6.3.1.2.2. By Vaccination

6.3.1.2.3. By Mode of Administration

6.3.2. Canada Pet Vaccine Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Animal Type

6.3.2.2.2. By Vaccination

6.3.2.2.3. By Mode of Administration

6.3.3. Mexico Pet Vaccine Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Animal Type

6.3.3.2.2. By Vaccination

6.3.3.2.3. By Mode of Administration

7. Europe Pet Vaccine Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Animal Type

7.2.2. By Vaccination

7.2.3. By Mode of Administration

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Pet Vaccine Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Animal Type

7.3.1.2.2. By Vaccination

7.3.1.2.3. By Mode of Administration

7.3.2. United Kingdom Pet Vaccine Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Animal Type

7.3.2.2.2. By Vaccination

7.3.2.2.3. By Mode of Administration

7.3.3. Italy Pet Vaccine Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecasty

7.3.3.2.1. By Animal Type

7.3.3.2.2. By Vaccination

7.3.3.2.3. By Mode of Administration

7.3.4. France Pet Vaccine Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Animal Type

7.3.4.2.2. By Vaccination

7.3.4.2.3. By Mode of Administration

7.3.5. Spain Pet Vaccine Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Animal Type

7.3.5.2.2. By Vaccination

7.3.5.2.3. By Mode of Administration

8. Asia-Pacific Pet Vaccine Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Animal Type

8.2.2. By Vaccination

8.2.3. By Mode of Administration

8.2.4. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Pet Vaccine Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Animal Type

8.3.1.2.2. By Vaccination

8.3.1.2.3. By Mode of Administration

8.3.2. India Pet Vaccine Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Animal Type

8.3.2.2.2. By Vaccination

8.3.2.2.3. By Mode of Administration

8.3.3. Japan Pet Vaccine Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Animal Type

8.3.3.2.2. By Vaccination

8.3.3.2.3. By Mode of Administration

8.3.4. South Korea Pet Vaccine Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Animal Type

8.3.4.2.2. By Vaccination

8.3.4.2.3. By Mode of Administration

8.3.5. Australia Pet Vaccine Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Animal Type

8.3.5.2.2. By Vaccination

8.3.5.2.3. By Mode of Administration

9. South America Pet Vaccine Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Animal Type

9.2.2. By Vaccination

9.2.3. By Mode of Administration

9.2.4. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Pet Vaccine Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Animal Type

9.3.1.2.2. By Vaccination

9.3.1.2.3. By Mode of Administration

9.3.2. Argentina Pet Vaccine Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Animal Type

9.3.2.2.2. By Vaccination

9.3.2.2.3. By Mode of Administration

9.3.3. Colombia Pet Vaccine Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Animal Type

9.3.3.2.2. By Vaccination

9.3.3.2.3. By Mode of Administration

10. Middle East and Africa Pet Vaccine Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Animal Type

10.2.2. By Vaccination

10.2.3. By Mode of Administration

10.2.4. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Pet Vaccine Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Animal Type

10.3.1.2.2. By Vaccination

10.3.1.2.3. By Mode of Administration

10.3.2. Saudi Arabia Pet Vaccine Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Animal Type

10.3.2.2.2. By Vaccination

10.3.2.2.3. By Mode of Administration

10.3.3. UAE Pet Vaccine Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Animal Type

10.3.3.2.2. By Vaccination

10.3.3.2.3. By Mode of Administration

11. Market Dynamics

11.1. Drivers & Challenges

12. Market Trends & Developments

12.1. Recent Developments

12.2. Product Launches

12.3. Mergers & Acquisition

13. Global Pet Vaccine Market: SWOT Analysis

14. Competitive Landscape

14.1. Bayer AG

14.1.1. Business Overview

14.1.2. Treatment Offerings

14.1.3. Recent Developments

14.1.4. Key Personnel

14.1.5. SWOT Analysis

14.2. Elanco US Inc.

14.3. Merck KGaA

14.4. Merial Inc.

14.5. Virbac SA

14.6. Zoetis Inc

14.7. Phibro Animal Health Corporation

14.8. Boehringer Ingelheim GmbH

14.9. Tianjin Ringpu Bio-Technology Co., Ltd

14.10.Vetoquinol SA

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Pet Vaccine Market in 2022?

The market size of the Global Pet Vaccine Market was estimated to be USD 1.12 billion in 2022.

What is Pet Vaccine?

A pet vaccine is a biological product administered to companion animals, such as dogs and cats, to stimulate their immune systems against specific diseases. It helps prevent or reduce the severity of infections, protecting both pets and potentially public health by reducing the risk of zoonotic disease transmission.

Who are the top players operating in the Global Pet Vaccine Market in 2022?

Bayer AG, Elanco US Inc, Merck KGaA, Merial Inc, Virbac SA, Zoetis Inc, Phibro Animal Health Corporation, Boehringer Ingelheim GmbH, Tianjin Ringpu Bio-Technology Co., Ltd, Vetoquinol SA are the top players operating in the Global Pet Vaccine Market in 2022.

What are the major drivers for the Global Pet Vaccine Market?

Growing awareness of preventive healthcare and Increased prevalence of zoonotic diseases are the major drivers for the Global Pet Vaccine Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Pet Vaccine Market to Grow with a CAGR of 6.15% through 2028

Nov, 2023

Vaccine advancements and Emerging infectious diseases are factors driving the global Pet Vaccine market in the forecast period 2024-2028.